MedTrace Logo

Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus

NCT04069949 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2019-10-25

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of sorafenib plus toripalimab for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).

Conditions

  • Unresectable Hepatocellular Cancer
  • Portal Vein Tumor Thrombus

Interventions

DRUG

sorafenib; toripalimab

Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Qiu Li, Professor · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2020-10-01
Completion
2021-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04069949 on ClinicalTrials.gov